Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Net Income (2022 - 2025)

Historic Net Income for 60 Degrees Pharmaceuticals (SXTP) over the last 4 years, with Q3 2025 value amounting to -$2.3 million.

  • 60 Degrees Pharmaceuticals' Net Income fell 724.55% to -$2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.0 million, marking a year-over-year decrease of 31.73%. This contributed to the annual value of -$8.0 million for FY2024, which is 10860.2% down from last year.
  • As of Q3 2025, 60 Degrees Pharmaceuticals' Net Income stood at -$2.3 million, which was down 724.55% from -$1.7 million recorded in Q2 2025.
  • In the past 5 years, 60 Degrees Pharmaceuticals' Net Income registered a high of $4.2 million during Q3 2023, and its lowest value of -$4.2 million during Q2 2024.
  • Its 4-year average for Net Income is -$1.6 million, with a median of -$2.0 million in 2023.
  • In the last 5 years, 60 Degrees Pharmaceuticals' Net Income surged by 38769.81% in 2023 and then crashed by 53863.71% in 2025.
  • Over the past 4 years, 60 Degrees Pharmaceuticals' Net Income (Quarter) stood at -$1.7 million in 2022, then fell by 22.55% to -$2.0 million in 2023, then decreased by 0.13% to -$2.0 million in 2024, then decreased by 13.09% to -$2.3 million in 2025.
  • Its last three reported values are -$2.3 million in Q3 2025, -$1.7 million for Q2 2025, and -$1.9 million during Q1 2025.